Anti-PDL1 antibody-drug conjugate and its application

The novel antibody-drug conjugate TP-[L1-L2-L3-D] k addresses the limitations of current anti-PDL1 antibodies by enhancing therapeutic efficacy and reducing toxicity, effectively targeting PDL1-positive cells and inhibiting tumors with improved cytotoxicity and specificity.

JP2026517857APending Publication Date: 2026-06-02SHANGHAI HENLIUS BIOTECH INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SHANGHAI HENLIUS BIOTECH INC
Filing Date
2024-05-09
Publication Date
2026-06-02

Smart Images

  • Figure 2026517857000048
    Figure 2026517857000048
  • Figure 2026517857000049
    Figure 2026517857000049
  • Figure 2026517857000050
    Figure 2026517857000050
Patent Text Reader

Abstract

This invention relates to antibody-drug conjugates (ADCs) and their applications. Specifically, it concerns novel anti-PDL1 antibody-drug conjugates and methods and applications for treating diseases or symptoms associated with PDL1 expression.
Need to check novelty before this filing date? Find Prior Art